Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Silencing of GULP1 gene expression plays important role in ovarian carcinogenesis

Johns Hopkins researchers in collaboration with Insilico Medicine, a biotechnology company based in Rockville Maryland, identify that silencing of the GULP1 gene expression by methylation plays an important role in ovarian carcinogenesis.

7 Aug 2018

Researchers discover new mechanism linked to inherited breast, ovarian cancer

Researchers from Manchester University NHS Foundation Trust and The University of Manchester have identified a new mechanism which switches off a gene in families affected by breast and ovarian cancer.

3 Aug 2018

BRAF inhibitors may be effective at treating rare ovarian cancer, study shows

New research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.

30 Jul 2018

Researchers discover various mechanisms of resistance to cancer therapy

An international research team under the co-direction of the University of Bern and the Netherlands Cancer Institute has discovered various mechanisms of resistance to cancer therapy. The findings help researchers to understand the self-repair of cancer cells after a therapy and thus help to fight resistant tumours more efficiently.

30 Jul 2018

Study uncovers new protein complex that shields broken DNA ends

Scientists have made a major discovery about how cells repair broken strands of DNA that could have huge implications for the treatment of cancer.

19 Jul 2018

New technique measures how well cancer drugs reach their targets

Scientists have developed a technique that allows them to measure how well cancer drugs reach their targets inside the body.

13 Jul 2018

New approach sheds light on effects of drugs on cancer cells

A new approach established at the University of Zurich sheds light on the effects of anti-cancer drugs and the defense mechanisms of cancer cells.

11 Jul 2018

Study does not find causal association between assisted reproduction and ovarian cancer risk

Following concerns over many years that hormonal stimulation of the ovaries necessary for IVF may increase the risk of ovarian cancer, a nationwide cohort study from Denmark has now concluded that any perceived increase in risk is actually a statistical bias resulting from vigilant diagnosis at the time of treatment.

3 Jul 2018

Mayo researchers determine how DNA repair protein gets to the site of damage

Damage to DNA is a daily occurrence but one that human cells have evolved to manage. Now, in a new paper published in Nature Structural & Molecular Biology, Mayo researchers have determined how one DNA repair protein gets to the site of DNA damage. The authors say they hope this discovery research will help identify new therapies for ovarian cancer.

3 Jul 2018

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency has approved LYNPARZA tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2 -negative breast cancer who have received prior chemotherapy.

2 Jul 2018

Modified natural killer cells may be new player in CAR-T immunotherapies

Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.

29 Jun 2018

Genetic subset of prostate cancer may benefit from combination checkpoint immunotherapy

Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy released a study investigating the use of combination checkpoint immunotherapy in the treatment of a lethal form of advanced prostate cancer.

25 Jun 2018

KIYATEC enrolls first patients with solid tumors in clinical study of its EV3D drug response assay

KIYATEC, Inc. today announced the enrollment of the first patients in a U.S. clinical study of its Ex Vivo 3D drug response assay across several difficult-to-treat solid tumors.

20 Jun 2018

Risks of cancer and mortality found to be lowest in light drinkers

The risk of mortality, and of developing a number of cancers, is lowest in light drinkers consuming an average of less than one drink per day across their lifetime, and the risk of some cancers increases with each additional drink per week, according to a new study, published this week in PLOS Medicine by Andrew Kunzmann of Queen’s University Belfast, and colleagues.

20 Jun 2018

Study finds combined risk of death and developing cancer to be lowest in light drinkers

A new study, led by Dr Andrew Kunzmann, researcher from the School of Medicine, Dentistry and Biomedical Sciences at Queen's University Belfast, has found the combined risk of death and developing a number of cancers is lowest in light drinkers, consuming less than one drink per day, and increases with each additional drink per week.

19 Jun 2018

Scientists identify new subtype of prostate cancer

Researchers led by the University of Michigan Rogel Cancer Center have identified a new subtype of prostate cancer that occurs in about 7 percent of patients with advanced disease.

14 Jun 2018

Study opens new potential avenue for treating ovarian cancer

Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer.

14 Jun 2018

Charity introduces new Hereditary Cancer Risk Tool to fight ovarian cancer

Around 15% of ovarian cancer cases are linked to genetic mutations such as BRCA1, BRCA2 and Lynch Syndrome, which increase an individual's likelihood of developing ovarian and other cancers. This equates to over 1,000 women a year in the UK whose lives could potentially be saved.

13 Jun 2018

OGT increases NGS cancer panel content to provide more flexibility for customization

Oxford Gene Technology, The Molecular Genetics Company, has expanded its SureSeq myPanel™ NGS Custom Cancer Panel content - now covering 120 fully optimized cancer related genes.

From Oxford Gene Technology 13 Jun 2018

Research identifies new genetic variations that could indicate higher prostate cancer risk

As the result of a six-year long research process, Fredrick R. Schumacher, PhD, a cancer epidemiology researcher at Case Western Reserve University School of Medicine, and an international team of more than 100 colleagues have identified 63 new genetic variations that could indicate higher risk of prostate cancer in men of European descent.

12 Jun 2018